These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 17109733

  • 1. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients.
    Kreijveld E, Koenen HJ, Klasen IS, Hilbrands LB, Joosten I.
    Am J Transplant; 2007 Jan; 7(1):249-55. PubMed ID: 17109733
    [Abstract] [Full Text] [Related]

  • 2. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation.
    Wang Z, Xiao L, Shi BY, Qian YY, Bai HW, Chang JY, Cai M.
    Transpl Immunol; 2008 Apr; 19(1):69-73. PubMed ID: 18346640
    [Abstract] [Full Text] [Related]

  • 3. Clinical rejection and persistent immune regulation in kidney transplant patients.
    Hendrikx TK, Klepper M, Ijzermans J, Weimar W, Baan CC.
    Transpl Immunol; 2009 Jul; 21(3):129-35. PubMed ID: 19398001
    [Abstract] [Full Text] [Related]

  • 4. Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study.
    Li J, Li X, Tan M, Lin B, Hou S, Qian W, Li B, Zhang D, Zhou B, Wang H, Zhu T, Guo Y.
    MAbs; 2009 Jul; 1(1):49-55. PubMed ID: 20046574
    [Abstract] [Full Text] [Related]

  • 5. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.
    Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, McFarland H, Jacobson S.
    Arch Neurol; 2009 Apr; 66(4):471-9. PubMed ID: 19364932
    [Abstract] [Full Text] [Related]

  • 6. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
    Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ, Adema GJ.
    Clin Cancer Res; 2010 Oct 15; 16(20):5067-78. PubMed ID: 20736326
    [Abstract] [Full Text] [Related]

  • 7. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation.
    Wang Z, Shi BY, Qian YY, Cai M, Wang Q.
    Clin Exp Immunol; 2009 Mar 15; 155(3):496-503. PubMed ID: 19141125
    [Abstract] [Full Text] [Related]

  • 8. [Regulatory T cells in kidney transplant recipients].
    Libetta C, Portalupi V, Margiotta E, Sepe V, Canevari M, Meloni F, Morosini M, Dal Canton A.
    G Ital Nefrol; 2009 Mar 15; 26 Suppl 45():S54-7. PubMed ID: 19382095
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
    Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C.
    Biol Blood Marrow Transplant; 2017 Mar 15; 23(3):405-411. PubMed ID: 28007665
    [Abstract] [Full Text] [Related]

  • 11. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R.
    Clin Transplant; 2000 Dec 15; 14(6):550-4. PubMed ID: 11127307
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of CD4+ CD25+/- CD39+ T-cell populations in peripheral blood of patients following kidney transplantation and during acute allograft rejection.
    McRae JL, Chia JS, Pommey SA, Dwyer KM.
    Nephrology (Carlton); 2017 Jul 15; 22(7):505-512. PubMed ID: 27517975
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR, Faulds D.
    Drugs; 1999 Dec 15; 58(6):1029-42. PubMed ID: 10651389
    [Abstract] [Full Text] [Related]

  • 15. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR.
    Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy.
    Krystufkova E, Sekerkova A, Striz I, Brabcova I, Girmanova E, Viklicky O.
    Nephrol Dial Transplant; 2012 Jun 15; 27(6):2576-82. PubMed ID: 22167587
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Jun 15; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.